Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Aligos Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ALGS
Nasdaq
8731
https://www.aligos.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aligos Therapeutics Inc
Aligos Therapeutics, Inc. (ALGS) Just Flashed Golden Cross Signal: Do You Buy?
- Mar 27th, 2024 1:55 pm
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
- Mar 27th, 2024 12:00 pm
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
- Mar 18th, 2024 12:00 pm
Aligos Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
- Mar 14th, 2024 10:16 am
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
- Mar 12th, 2024 8:05 pm
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
- Mar 5th, 2024 9:05 pm
Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024
- Feb 26th, 2024 1:00 pm
Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024
- Feb 20th, 2024 1:00 pm
Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments
- Feb 13th, 2024 1:00 pm
Is Aligos Therapeutics (ALGS) Stock Outpacing Its Medical Peers This Year?
- Jan 5th, 2024 2:40 pm
Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)
- Dec 7th, 2023 9:05 pm
13 Stocks Insiders are Buying Now
- Nov 24th, 2023 3:26 pm
Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference
- Nov 20th, 2023 9:05 pm
Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting® 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile
- Nov 13th, 2023 1:00 pm
Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)
- Nov 10th, 2023 1:05 pm
Aligos Therapeutics to Present Multiple Posters at AASLD’s The Liver Meeting® 2023, Highlighting Progress for Its Clinical Stage Portfolio, including Lead THR-β Agonist for the Treatment of NASH, ALG-055009; ALG-000184, the Company’s Lead CAM-E Molecule, and Updates on Several Preclinical Candidates for the Treatment of Chronic Hepatitis B, in Addition to the Recently Announced Late Breaker Poster (#5028-C)
- Nov 7th, 2023 1:00 pm
Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data
- Nov 3rd, 2023 8:30 pm
Aligos Therapeutics Inc (ALGS) Reports Q3 2023 Financial Results and Business Progress
- Nov 2nd, 2023 10:57 pm
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results
- Nov 2nd, 2023 8:05 pm
Aligos Therapeutics to Announce 3rd Quarter Results on November 2, 2023
- Oct 26th, 2023 8:05 pm
Scroll